• The FDA recently approved Zepbound, a new injectable medication, to treat chronic weight management.
• The medication features the same compound that’s in the type 2 diabetes medication Mounjaro, but competes directly with Wegovy, another weight loss drug.
• Experts recommend people have personalized conversations with a doctor to decide if a weight loss medication is the correct choice for their health.
  

There’s another new weight loss medication on the market.

On November 8, the Food and Drug Administration (FDA) approved Zepbound for adults with overweight or obesity and at least one weight-related condition, such as high blood pressure or high cholesterol.

The approval came after two studies found that people taking 15 milligrams (mg) of Zepbound lost 18% and 12% of their body weight respectively, as compared to a placebo group.

These results indicate the medication may be more potent than Wegovy.

“People have been waiting for the official FDA approval,” Rekha Kumar, MD, an endocrinologist at Weill Cornell Medicine and NewYork-Presbyterian, told Health.

“[Zepbound] is known to be the most effective weight loss medicine that currently exists,” she said.

Between Zepbound and Wegovy, as well as Mounjaro and Ozempic, the field of weight loss and type 2 diabetes medications is starting to become more crowded.

Here are the differences between Zepbound and existing injectable weight loss medications, as well as what consumers need to know when choosing the right medication.

Comparing Wegovy, Ozempic, Zepbound, and Mounjaro

Zepbound, Wegovy, Mounjaro, and Ozempic all follow a simple pattern that makes it easier to understand how they compare to one another, Dina Peralta-Reich, MD, director of New York Weight Wellness Medicine, told Health.

Wegovy and Ozempic include the same compound—semaglutide—but are approved for managing weight loss and type 2 diabetes, respectively. The same is true for Zepbound and Mounjaro.

“Zepbound is tirzepatide, which already exists with the brand name of Mounjaro,” Peralta-Reich said. “Tirzepatide has been used for diabetes, but we have been using it off-label for the management of weight.”

Now that Zepbound is officially FDA approved, people looking to take tirzepatide for weight loss can seek out that medication instead of using Mounjaro—that medication is only approved to treat type 2 diabetes, though people who use it often lose weight.

Though Zepbound and Wegovy both help people lose weight, and Mounjaro and Ozempic help manage type 2 diabetes, the actual medications function differently. 

Ozempic was first approved by the FDA in late 2017, and has since made headlines both for its intended use—treating type 2 diabetes—and for its off-label weight loss use, particularly among celebrities.

The active ingredient in Ozempic is semaglutide, which copies the glucagon-like peptide-1 (GLP-1) hormone. This helps the body produce more insulin and signals a feeling of fullness in the brain.

Ozempic is taken via a weekly injection. To start, patients will take 0.25 mg for one month, and 0.50 mg for at least a month after that. Beyond that time frame, people can take either 1 or 2 mg to control blood sugar.

Novo Nordisk—the makers of Ozempic—don’t say how long people should take the medication for, only that it’s “safe and effective when used as indicated for the treatment of adults with type 2 diabetes to lower blood sugar.”

Semaglutide is also the active ingredient in Wegovy, which was first approved in June 2021.

Wegovy is also administered with a once-weekly injection.

At first, the dosing for Wegovy is also fairly similar to Ozempic—people on Wegovy can be bumped from 0.25 mg to 0.50 mg to 1 mg over three months. After four months, however, Wegovy is taken as a 1.7 mg injection, and finally a 2.4 mg injection from month five onwards.

Wegovy can have quite substantial effects—about one in three people who take the drug lose 20% of their body weight, or 46 pounds on average.

People who take semaglutide could see similar side effects from either Ozempic or Wegovy. The most common issues include nausea, vomiting, diarrhea, abdominal pain, and constipation, though more serious side effects such as pancreatitis, gastroparesis, and bowel obstruction have been reported.

The ingredient activates hormone receptors for GLP-1, and for another hormone called GIP, or glucose-dependent insulinotropic polypeptide, Jenny Tong, MD, MPH, an associate professor in the division of endocrinology at the University of Washington School of Medicine, told Health.

She explained that both of these hormones “increase insulin secretion to help disperse glucose.”

This is how Mounjaro, which is approved for type 2 diabetes management, can help lower blood sugar and improve insulin resistance.

Similarly to semaglutide, tirzepatide can help reduce a person’s food intake, which explains the drug’s ability to help people lose weight.

“GLP-1s help you decrease your appetite and increase your satiety. And it works at the level of the stomach, the brain, and in the pancreas,” Peralta-Reich said. “The GIP works at the level of the brain, decreasing appetite and it also supposedly improves how your body breaks down fats and sugars.”

The chemical compound for both Mounjaro and Zepbound is the same, as is the dosing, Kumar explained.

Mounjaro and Zepbound are both given as a 2.5 mg weekly injection for one month, then increased to 5 mg each week for at least another month. Beyond that, people can slowly increase their dosage if necessary—to a maximum of 15 mg.

Zepbound’s effect on a person’s weight can be even more substantial than Wegovy’s. At the highest dose, one in three people lost 25% of their body weight, or 58 pounds.

Side effects also seem to be “very similar” to semaglutide, Peralta-Reich said. Both active ingredients can cause nausea, diarrhea, vomiting, constipation, indigestion, and stomach pain, among other side effects.